<DOC>
	<DOC>NCT00703469</DOC>
	<brief_summary>This study examines the safety, tolerability, and immunogenicity of a single dose of MDX-1106 in patients with active hepatitis C genotype 1 or mixed hepatitis C genotype infection.</brief_summary>
	<brief_title>A Study of MDX-1106 to Treat Patients With Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Infection with hepatitis C genotype 1 or mixed hepatitis C genotype; Asymptomatic or nearly asymptomatic from hepatitis C; Previous therapy with interferon and ribavirin or peginterferon and ribavirin without an SVR or relapsed following an SVR;or Interferon naive subjects Chronically infected (at least 6 months since diagnosis) HCVpositive subjects; No evidence of bridging necrosis or cirrhosis; Liver biopsy within the last 2 years Acute hepatitis C infection History of prior malignancy, acquired or inherited immunodeficiency or autoimmune disease either documented or anecdotal;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Hep C</keyword>
</DOC>